TY - JOUR

T1 - A contemporary systematic review on repartition of HPV-positivity in oropharyngeal cancer worldwide

AU - Carlander, Amanda F.

AU - Jakobsen, Kathrine K.

AU - Bendtsen, Simone K.

AU - Garset-Zamani, Martin

AU - Lynggaard, Charlotte D.

AU - Jensen, Jakob Schmidt

AU - Grønhøj, Christian

AU - Von Buchwald, Christian

N1 - Funding Information: Funding: Amanda-Louise Fenger Carlander was funded by Candys Foundation (2.785.000 DKkr). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Publisher Copyright: © 2021 by the authors.

PY - 2021/7

Y1 - 2021/7

N2 - Significant variation in human papillomavirus (HPV) prevalence in oropharyngeal squamous cell carcinoma (OPSCC) across countries ranging from 11% in Brazil to 74% in New Zealand has been reported earlier. The aim of this study was to systematically review the most recently published studies on the occurrence of HPV in OPSCC globally. PubMed and Embase were systematically searched for articles assessing the occurrence of HPV+ OPSCC published between January 2016 and May 2021. Studies with a study period including 2015 and the following years were included. Both HPV DNA and/or p16 were accepted as indicators of HPV+ OPSCC. 31 studies were enrolled comprising 49,564 patients with OPSCC (range 12–42,024 patients per study) from 26 different countries covering all continents. The lowest occurrences of HPV+ OPSCC were observed in India (0%) and Spain (10%) and the highest occurrences were observed in Lebanon (85%) and Sweden (70%). We observed great variation in HPV prevalence in OPSCC worldwide varying from 0% to 85%. The highest occurrences of HPV+ OPSCC were found in general in Northern European countries, USA, Lebanon, China, and South Korea. We observed a trend of increase in HPV-positivity, indicating a mounting burden of HPV+ OPSCC.

AB - Significant variation in human papillomavirus (HPV) prevalence in oropharyngeal squamous cell carcinoma (OPSCC) across countries ranging from 11% in Brazil to 74% in New Zealand has been reported earlier. The aim of this study was to systematically review the most recently published studies on the occurrence of HPV in OPSCC globally. PubMed and Embase were systematically searched for articles assessing the occurrence of HPV+ OPSCC published between January 2016 and May 2021. Studies with a study period including 2015 and the following years were included. Both HPV DNA and/or p16 were accepted as indicators of HPV+ OPSCC. 31 studies were enrolled comprising 49,564 patients with OPSCC (range 12–42,024 patients per study) from 26 different countries covering all continents. The lowest occurrences of HPV+ OPSCC were observed in India (0%) and Spain (10%) and the highest occurrences were observed in Lebanon (85%) and Sweden (70%). We observed great variation in HPV prevalence in OPSCC worldwide varying from 0% to 85%. The highest occurrences of HPV+ OPSCC were found in general in Northern European countries, USA, Lebanon, China, and South Korea. We observed a trend of increase in HPV-positivity, indicating a mounting burden of HPV+ OPSCC.

KW - Global

KW - Head and neck cancer

KW - HPV genotype

KW - Human papillomavirus

KW - Oropharyngeal cancer

KW - Oropharyngeal squamous cell carcinoma

KW - Prevalence

KW - Worldwide

U2 - 10.3390/v13071326

DO - 10.3390/v13071326

M3 - Review

C2 - 34372532

AN - SCOPUS:85111083145

VL - 13

JO - Viruses

JF - Viruses

SN - 1999-4915

IS - 7

M1 - 1326

ER -